Immunogenicity and Safety of a Third Dose and Immune Persistence of BBIBP-Corv Vaccine in Elderly People With Chronic Bronchitis and COPD

China National Biotec Group (CNBG)

Status and phase

Unknown

Phase 4

Conditions

COVID-19

Chronic Bronchitis

COPD

Treatments

Biological: Inactivated COVID-19 vaccine

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT05104216

BIBP2021COPD-third dose

Details and patient eligibility

About

Evaluation of immunogenicity, safety and persistence of the subjects aged 60 years and above with chronic bronchitis and chronic obstructive pulmonary disease received the third dose of inactivated COVID-19 vaccine .

Full description

The subjects aged 60 years and above with chronic bronchitis and chronic obstructive pulmonary disease recruited to receive a third dose of inactivated COVID-19 vaccine.

Blood samples will be collected 3 times: before the third dose of vaccinatioin，28 days and 6 months after the third dose of vaccination.

Any local or systemic adverse events that occurred within 21 days after vaccination will be recorded.

Enrollment

400 estimated patients

Sex

All

Ages

60+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Subjects aged 60 and above with full capacity for civil conduct;
Chronic bronchitis (or chronic obstructive pulmonary disease) diagnosed by a medical institution at level I or above;
Body temperature < 37.3 ° C confirmed by clinical examination before enrollment ;
Able and willing to complete the entire study plan during the study follow-up period;
Have the ability to understand the study procedures, voluntarily sign informed consent, and comply with the requirements of the clinical study protocol;
Subjects participating in the past clinical trial have completed two doses of COVID-19 vaccine and blood collection before and after immunization;

Exclusion criteria

Subjects were previously confirmed cases of COVID-19 or asymptomatic infected persons;
Being allergic to any component of vaccines (including excipients) ;
Injection of non-specific immunoglobulin within 1 month before enrollment;
Injection of live attenuated vaccines within 1 month and injection of other vaccines within 14 days before enrollment;
Subjects who have experienced severe allergic reactions to vaccines (e.g. acute anaphylaxis, urticaria, angioneurotic edema, dyspnea, etc.);
Having uncontrolled epilepsy and other progressive neurological disorders and a history of Guillain-Barre syndrome;
Having severe liver and kidney diseases, malignant tumors, acute diseases or acute episodes of chronic diseases;
Have been diagnosed with congenital or acquired immunodeficiency, HIV infection, lymphoma, leukaemia or other autoimmune diseases;
Have been diagnosed with thrombocytopenia or other clotting disorders that may contraindicate subcutaneous injection;
During an acute episode of chronic bronchitis/chronic obstructive pulmonary disease;
Subjects who had vaccine-related adverse reactions after the second dose;
Having high fever (axillary temperature ≥39.0℃) for three days after the second dose of inoculation, or severe allergic reaction;
Having any adverse nervous system reaction after the second dose;
During the acute onset of a chronic disease, or the recovery of acute complications less than two weeks;
Other reasons for exclusion considered by the investigator.